ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7

ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the 30th Annual Prostate Cancer...

Related Keywords

Andrew Laccetti , Prostate Cancer Foundation Scientific , Drug Administration , Memorial Sloan Kettering Cancer Center , Essa Pharma Inc , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Presenting Author , Fast Track , Markets ,